Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud related to the company's glucose monitoring products, specifically the G6 and G7 models, during the period from July 26, 2024, to September 17, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that DexCom made unauthorized material design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [2]. - It is alleged that these design changes compromised the reliability of the G6 and G7 devices, posing a significant health risk to users who depend on accurate glucose readings [2]. - The complaint asserts that the enhancements claimed for the G7 device, including its reliability and accuracy, were overstated by the defendants [2]. - The lawsuit also contends that the true extent of the issues and health risks associated with the G7 devices was downplayed by the defendants [2]. - As a result of these actions, DexCom faced increased risks of regulatory scrutiny and potential legal, reputational, and financial harm [2]. - The public statements made by the defendants were characterized as materially false and misleading throughout the relevant time period [2]. Group 2: Legal Process and Participation - Investors who suffered losses in DexCom, Inc. during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require individuals to serve as lead plaintiffs to be eligible for potential compensation [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]. - The firm has extensive experience in complex securities litigation, supported by a team of over 70 employees [4].

Core Points - A class action securities lawsuit has been filed against DexCom, Inc. to recover losses for shareholders affected by alleged securities fraud between July 26, 2024, and September 17, 2025 [2] - The lawsuit alleges that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, which rendered them less reliable and posed health risks to users [3] Company Details - The complaint claims that the defendants overstated the enhancements and reliability of the G7 device, downplayed the severity of issues with the G7, and subjected DexCom to increased regulatory scrutiny and potential legal repercussions [3] - The lawsuit indicates that the public statements made by the defendants were materially false and misleading throughout the relevant time period [3] Next Steps - Shareholders who suffered losses in DexCom, Inc. stock during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4] Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the United States [5]

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud following significant stock declines attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - The lawsuit is based on claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in DexCom securities [2]. - Investors have until December 26, 2025, to request to lead the case, which is pending in the U.S. District Court for the Southern District of New York [2]. Group 2: Product Issues - DexCom manufactures continuous glucose monitoring systems, including the G6 and G7, which were marketed as highly accurate [3]. - Allegations state that unauthorized design changes were made to the G6 and G7, compromising their accuracy and exposing users to health risks [4]. Group 3: Stock Performance - DexCom's stock experienced significant declines due to quality issues with the G6 and G7, including a drop of $7.12 per share (over 9%) following an FDA warning letter on March 7, 2025 [5]. - After the FDA published the warning letter on March 25, 2025, the stock fell another $3.19 per share (over 4%) [6]. - A report by Hunterbrook on September 18, 2025, revealed severe issues with the G7, leading to a nearly 12% drop of $8.99 per share [7].

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [5]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [5]. - The allegations suggest that these misrepresentations subjected DexCom to increased regulatory scrutiny and potential legal and financial repercussions [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by December 29, 2025, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [4] - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [4] - The allegations suggest that these actions subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging misleading statements and undisclosed risks related to the company's glucose monitoring products [1][3]. Summary by Sections Allegations - The complaint claims that during the class period from July 26, 2024, to September 17, 2025, DexCom made unauthorized design changes to its G6 and G7 glucose monitoring devices, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes allegedly made the G6 and G7 devices less reliable, posing a material health risk to users who depend on them for accurate glucose readings [3]. - The enhancements claimed for the G7 device, including its reliability and accuracy, were reportedly overstated by the defendants [3]. - The true scope and severity of the issues with the G7 devices were downplayed, increasing the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [3]. - As a result, the public statements made by the defendants were considered materially false and misleading throughout the relevant period [3]. Next Steps for Shareholders - Shareholders who purchased shares of DXCM during the specified class period are encouraged to register for the class action by December 26, 2025, to potentially be appointed as lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who have suffered losses due to misleading statements or omissions [5].

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) for violations of the federal securities laws on behalf of investors who purchased or acquired DexCom securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”). On October 27, 2025, a complaint was filed against the Company and cert ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit due to allegations of misleading statements and undisclosed material changes to their glucose monitoring products, the G6 and G7, which may pose health risks to users [1]. Summary by Sections Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which rendered them less reliable than previous versions, posing a material health risk to users [1]. - It is claimed that the enhancements to the G7's reliability, accuracy, and functionality were overstated, and the company downplayed the severity of the issues related to the G7 devices [1]. - The allegations suggest that these actions increased the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [1]. Class Action Details - The class period for the lawsuit is from July 26, 2024, to September 17, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is December 26, 2025, with no cost or obligation to participate in the case [2]. Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit and illegal business practices, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud, alleging that the company misled investors about the reliability and accuracy of its continuous glucose monitoring systems, leading to significant stock declines [2][4]. Company Overview - DexCom, Inc. specializes in manufacturing continuous glucose monitoring (CGM) systems, including the Dexcom G6 and G7 models [5]. Allegations and Issues - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7, which compromised the accuracy of the devices and posed potential health risks to customers [6]. - The company allegedly prioritized cost-cutting over safety, ignoring critical safety issues [6]. Stock Performance and Impact - DexCom's stock experienced significant declines due to revelations about quality issues: - On March 7, 2025, the stock fell by $7.12 per share (over 9%) following an FDA warning letter regarding manufacturing concerns [7]. - After the FDA's public disclosure on March 25, 2025, the stock dropped another $3.19 per share (over 4%) [8]. - A report published on September 18, 2025, led to a nearly 12% decline, with the stock dropping $8.99 per share over two trading days [9].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, about the upcoming lead plaintiff deadline on December 29, 2025, for a class action lawsuit related to misleading statements made by the company [1]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to serve as lead plaintiff is December 29, 2025, which requires a motion to the Court [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the company downplayed the severity of issues related to the G7 devices, leading to increased regulatory scrutiny and potential legal and financial repercussions [5]. - The lawsuit asserts that the public statements made by DexCom were materially false and misleading, resulting in investor damages when the true information became public [5].